Literature DB >> 11340063

Binding of ligands and activation of transcription by nuclear receptors.

A C Steinmetz1, J P Renaud, D Moras.   

Abstract

Nuclear receptors (NRs) form a superfamily of ligand-inducible transcription factors composed of several domains. Recent structural studies focused on domain E, which harbors the ligand-binding site and the ligand-dependent transcription activation function AF-2. Structures of single representatives in an increasing number of various complexes as well as new structures of further NRs addressed issues such as discrimination of ligands, superagonism, isotype specificity, and partial agonism. Until today, one unique transcriptionally active form of domain E was determined; however, divergent tertiary structures of apo-forms and transcriptionally inactive forms are known. Thus, recent results link the transformation of NRs upon ligand binding to principles of protein folding. Furthermore, the ensemble of NR structures, including those of DNA-binding domains, provides one of the foundations for the understanding of interactions with transcription intermediary factors up to the characterization of the link between NR complexes and the basal transcriptional machinery at the structural level.

Mesh:

Substances:

Year:  2001        PMID: 11340063     DOI: 10.1146/annurev.biophys.30.1.329

Source DB:  PubMed          Journal:  Annu Rev Biophys Biomol Struct        ISSN: 1056-8700


  53 in total

1.  X-ray structure of the orphan nuclear receptor RORbeta ligand-binding domain in the active conformation.

Authors:  C Stehlin; J M Wurtz; A Steinmetz; E Greiner; R Schüle; D Moras; J P Renaud
Journal:  EMBO J       Date:  2001-11-01       Impact factor: 11.598

2.  Molecular origins for the dominant negative function of human glucocorticoid receptor beta.

Authors:  Matthew R Yudt; Christine M Jewell; Rachelle J Bienstock; John A Cidlowski
Journal:  Mol Cell Biol       Date:  2003-06       Impact factor: 4.272

3.  Peroxisome proliferator-activated receptors target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis.

Authors:  Bernard Pirard
Journal:  J Comput Aided Mol Des       Date:  2003-11       Impact factor: 3.686

4.  An analysis of core deformations in protein superfamilies.

Authors:  Alejandra Leo-Macias; Pedro Lopez-Romero; Dmitry Lupyan; Daniel Zerbino; Angel R Ortiz
Journal:  Biophys J       Date:  2004-11-12       Impact factor: 4.033

5.  Anti-steroidogenic factor ARR19 inhibits testicular steroidogenesis through the suppression of Nur77 transactivation.

Authors:  Imteyaz Qamar; Eun-Yeung Gong; Yeawon Kim; Chin-Hee Song; Hyun Joo Lee; Sang-Young Chun; Keesook Lee
Journal:  J Biol Chem       Date:  2010-05-14       Impact factor: 5.157

6.  A critical role of helix 3-helix 5 interaction in steroid hormone receptor function.

Authors:  Junhui Zhang; Jessica Simisky; Francis T F Tsai; David S Geller
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-14       Impact factor: 11.205

Review 7.  Hsp90--from signal transduction to cell transformation.

Authors:  Mark A Brown; Li Zhu; Christian Schmidt; Philip W Tucker
Journal:  Biochem Biophys Res Commun       Date:  2007-08-20       Impact factor: 3.575

Review 8.  Generalized glucocorticoid resistance: clinical aspects, molecular mechanisms, and implications of a rare genetic disorder.

Authors:  Evangelia Charmandari; Tomoshige Kino; Takamasa Ichijo; George P Chrousos
Journal:  J Clin Endocrinol Metab       Date:  2008-03-04       Impact factor: 5.958

9.  1,1-Bis(3'-indolyl)-1-(p-chlorophenyl)methane activates the orphan nuclear receptor Nurr1 and inhibits bladder cancer growth.

Authors:  Teruo Inamoto; Sabitha Papineni; Sudhakar Chintharlapalli; Sung-Dae Cho; Stephen Safe; Ashish M Kamat
Journal:  Mol Cancer Ther       Date:  2008-12       Impact factor: 6.261

Review 10.  The obesity-related pathology and Th17 cells.

Authors:  Yusuke Endo; Koutaro Yokote; Toshinori Nakayama
Journal:  Cell Mol Life Sci       Date:  2016-10-18       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.